Product Description
Chong Kun Dang is developing CKD-391 as a treatment for Hyperlipidemias. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03793985)
Mechanisms of Action: Unknown
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Chong Kun Dang
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Korea
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Dyslipidemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| A52_11BE2309 | P1 |
Completed |
Dyslipidemia |
2024-01-07 |
23% |
2024-03-28 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
| A52_10BE2220 | P1 |
Completed |
Dyslipidemia |
2023-02-27 |
23% |
2023-10-07 |
Patient Enrollment|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|